CBD trial aims to stop psychosis before it starts
NCT ID NCT07434973
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether cannabidiol (CBD), a non-psychoactive cannabis compound, can reduce psychotic symptoms in 586 young people (ages 12-35) at high risk for psychosis. Participants take either CBD or a placebo daily for two years. The goal is to see if CBD can ease symptoms and prevent progression to full psychosis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL HIGH RISK FOR PSYCHOSIS (CHR) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Biobizkaia Health Research Institute (Asociación Instituto de Investigación Sanitaria)
Bilbao, Spain
Contact Email: •••••@•••••
Contact
-
Cambridgeshire and Peterborough NHS Foundation Trust
Cambridge, United Kingdom
Contact Email: •••••@•••••
-
Douglas Hospital Research Centre
Montreal, Canada
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Contact
-
Foundation for Biomedical Research of the Gregorio Marañón Hospital (FIBHGM)
Madrid, Spain
Contact Email: •••••@•••••
Contact
Contact Email: •••••@•••••
-
IRCCS Santa Lucia Foundation
Roma, Italy
Contact Email: •••••@•••••
Contact
Contact Email: •••••@•••••
-
Institute of Psychiatry, Psychology & Neuroscience, King's College London
London, United Kingdom
Contact Email: •••••@•••••
Contact
-
Ludwig Maximilian University Hospital
München, Germany
Contact Email: •••••@•••••
Contact
-
MedUni Vienna, Department of Child and Adolescent Psychiatry
Vienna, Austria
Contact Email: •••••@•••••
Contact
-
National and Kapodistrian University of Athens
Athens, Greece
Contact Email: •••••@•••••
Contact
-
Oxford Health NHS Foundation Trust (OHFT)
Oxford, United Kingdom
Contact Email: •••••@•••••
Contact
-
Psychiatric University Hospital (PUK)
Zurich, Switzerland
Contact Email: •••••@•••••
Contact
-
Stichting Amsterdam UMC
Amsterdam, Netherlands
Contact Email: •••••@•••••
Contact
-
University Hospital Turku
Turku, Finland
Contact Email: •••••@•••••
Contact
-
University Medical Center Schleswig-Holstein
Lübeck, Germany
Contact Email: •••••@•••••
Contact
-
University of Bari Aldo Moro
Bari, Italy
Contact Email: •••••@•••••
Contact
-
University of Campania L. Vanvitelli
Naples, Italy
Contact Email: •••••@•••••
Contact
-
University of Cologne, Faculty of Medicine and University Hospital of Cologne
Cologne, Germany
Contact Email: •••••@•••••
Contact
Contact Email: •••••@•••••
-
University of Pavia
Pavia, Italy
Contact Email: •••••@•••••
Contact
-
Vivantes Network for Health GmbH
Berlin, Germany
Contact Email: •••••@•••••
Contact